MENSNasdaqPharmaceutical Preparations

Jyong Biotech Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026

$1.93+0.09 (+4.89%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Jyong Biotech Ltd. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Research & Development	0.81	0.93	1.07
Selling, General & Admin	1.79	1.13	1.73
Selling & Marketing	0.05	0.04	0.05
General & Administrative	1.75	1.09	1.68
Operating Expenses	2.61	2.06	2.80
Operating Income	-2.61	-2.06	-2.80
Interest Expense	2.54	1.04	0.76
Interest & Investment Income	0.61	0.01	0.06
Other Non-Operating Income	-2.06	-0.96	-1.60
Gain (Loss) on Investments	0.00	–	–
Pretax Income	-4.67	-3.02	-4.40
Net Income	-4.67	-3.02	-4.40
EPS (Basic)(per share)	-0.06	-0.04	-0.06
EPS (Diluted)(per share)	-0.06	-0.04	-0.06
Shares Outstanding (Basic, Weighted)(shares)	73	72	72
Shares Outstanding (Diluted, Weighted)(shares)	73	72	72
EBITDA	-2.51	-1.94	-2.67

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 15.2%

Financial strength

Current ratio: 0.45
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 3.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –